Phase II Study of Amrubicin and Paclitaxel in Previously Treated Lung Cancer Patients
Phase 2
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000014019
- Lead Sponsor
- iigata Lung Cancer Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1 active concomitant malignancies,infections 2 symptomatic brain metastases 3 past history of severe allergic reactions to drugs 4 interstitial pneumonia identified by chest X-ray 5 bone metastasis or hypercalcemia required immediate treatment 6 other serious complications, such as uncontrolled angina pectoris,myocardial infarction, heart failure, uncontrolled diabetes mellitus or hypertension, uncontrolled massive pleural effusion or ascites. 7 allergie for PTX
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RR
- Secondary Outcome Measures
Name Time Method safety, PFS, OS